Oruka Therapeutics, Inc. beat EPS estimates 86% of the time across 7 reported quarters (6 beats, 1 misses), averaging +12.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.49 | $-0.55 | -12.2% | Miss | |
| Q1 FY26 | $-0.52 | $-0.48 | +7.7% | Beat | |
| Q4 FY25 | $-0.61 | $-0.45 | +26.2% | Beat | |
| Q3 FY25 | $-0.56 | $-0.55 | +1.8% | Beat | |
| Q2 FY25 | $-0.48 | $-0.46 | +4.2% | Beat | |
| Q1 FY25 | $-0.57 | $-0.40 | +29.8% | Beat | |
| Q4 FY24 | $-0.68 | $-0.49 | +27.9% | Beat | |
| Q3 FY24 | not reported | $-1.46 | not reported | not reported | |
| Q2 FY24 | not reported | $-0.18 | not reported | not reported | |
| Q1 FY24 | not reported | $-0.14 | not reported | not reported | |
| Q4 FY23 | not reported | $-0.08 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.10 | not reported | not reported |
Back to ORKA overview · ORKA holders · ORKA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.